Korean medical artificial intelligence (AI) imaging companies, such as Lunit, VUNO, and Coreline Soft, are set to unveil their latest advancements and research in AI-powered imaging solutions during the Radiological Society of North America 2023 (RSNA 2023) conference.

RSNA is the world's largest academic society in the field of Radiology, consisting of over 48,200 members in 145 countries. The group has held the event every year since the inauguration of the annual meeting in 1985.

Lunit, a leader in AI imaging analysis, announced its plans to present eight research papers demonstrating the effectiveness of its Lunit INSIGHT solution.

The company is focusing on major cancer diagnoses, such as lung and breast cancer, reflecting the real needs of the medical field and proving the clinical value of AI-based image analysis technology.

One key study they will present involves a double AI algorithm that acts as a safety net in chest X-ray interpretation aimed at maximizing reading efficiency for the majority of normal chest images typically encountered in actual clinical settings and preventing the omission of abnormal cases.

The company developed an autonomous algorithm for distinguishing normal/abnormal findings, known as the normal filtering (NF model), which initially analyzes X-ray images.

These images are then further analyzed using the commercial product Lunit INSIGHT CXR, an AI-based chest X-ray image analysis solution.

Lunit will also host a "Global INSIGHTS" session where they will invite world-renowned medical professionals to share their experiences with Lunit AI.

This event, spanning three days from Nov. 26 to 28, will feature speakers such as Dr. Karin Dembrower from Saint Göran Hospital in Sweden and Dr. David Gruen, former Chief Medical Officer (CMO) at IBM Watson Health. They will discuss the importance and practical utility of Lunit AI imaging analysis solutions in the actual medical field.

"We continue to prove the technical prowess of Lunit's AI solutions and introduce our products to the industry by presenting high-quality research results at the RSNA conference each year," Lunit CEO Suh Beom-seok (Brandon Suh) said. "Through this conference, we aim to further solidify our global leading position in the field of AI-based cancer diagnosis and continue our efforts to provide tangible benefits to medical professionals and patients."

VUNO is set to introduce its VUNO Med DeepBrain at RSNA 2023, a deep learning-based AI medical device recently approved by the U.S. FDA.

The device provides quick and detailed analysis of brain MRI images, segmenting the brain into more than 100 regions and quantifying the extent of atrophy. VUNO seeks to use this event to pursue aggressive business opportunities and discuss the clinical value and research achievements of its product, especially as it relates to the evolving field of dementia diagnosis.

VUNO plans to introduce the clinical value and key research findings of VUNO Med DeepBrain during presentation sessions at their exhibition booth, while also sharing future update plans for the product in response to the evolving trends in the clinical field of dementia diagnosis.

"At this year's RSNA 2023, we plan to focus on introducing our first FDA-approved product, VUNO Med DeepBrain, to the participants and concentrate on expanding partnerships with local medical institutions and companies that demand AI-based brain MRI quantification technology," VUNO CEO Lee Ye-ha said. "We will continue to strive to ensure that VUNO's medical imaging product line, which is spreading both domestically and internationally and recording steady sales growth, can assist more radiology medical professionals with efficient diagnostics."

Coreline Soft will also participate, presenting its comprehensive range of AI solutions, including the AVIEW LCS PLUS for simultaneous diagnosis of thoracic diseases.

The company intends to share insights and use cases from their global projects, underscoring the practicality of their products in clinical environments.

Coreline Soft will exhibit various software solutions such as AVIEW COPD for diagnosing chronic obstructive pulmonary disease, AVIEW CAC for cardiac conditions, and AVIEW Lung Texture for interstitial lung disease, among others.

The company also plans to present various papers related to AVIEW are scheduled to be presented.

Professor Catherine Jones from the Australian radiology network I-MED will deliver an oral presentation on a study comparing the performance of radiologists with and without AI assistance in routine clinical settings where nodules are incidentally discovered to evaluate the effectiveness of AVIEW LCS.

Other research to be presented includes quantitative analysis studies on bronchiectasis, asthma patients, an automatic bone density measurement algorithm, and combined pulmonary fibrosis and emphysema (CPFE) patients.

"We have focused on supplying medical AI solutions while understanding the unique environment and mid-to-long-term goals of each region globally," Coreline Soft CEO Kim Jin-kook said. "Based on these achievements, we plan to pursue strategic collaborations with key visitors from North America, Europe, and Asia."